Bispecifics for Third Line Therapy of R/R DLBCL

Experts transition their discussion to highlight the emergence of bispecific antibodies as an additional treatment option for patients with R/R DLBCL.

Related Keywords

,New Treatment Options ,Sequencing Therapeutic Choices ,Third Line Therapy ,Lymphoma ,Dlbcl ,Diffuse Largeb Cell Lymphoma ,Dlbcl Treatments ,Dlbcl Therapies ,Dlbcl Unmet Needs ,